Analysis of clinical risk factors in relapsed patients with class IV lupus nephritis

Wang,Jing; Qi,Yuan‑Yuan; Chen,Xue‑Ping; Ma,Li; Zhang,Li‑Li; Zhao,Yu; Wang,Mei

doi:10.3892/etm.2018.6130

Analysis of clinical risk factors in relapsed patients with class IV lupus nephritis

Authors:
- Jing Wang
- Yuan‑Yuan Qi
- Xue‑Ping Chen
- Li Ma
- Li‑Li Zhang
- Yu Zhao
- Mei Wang
View Affiliations

Affiliations: Department of Nephropathy, Lanzhou University Second Hospital, Lanzhou, Gansu 730000, P.R. China, Department of Obstetrics and Gynecology, Gansu Province People's Hospital, Lanzhou, Gansu 730000, P.R. China
Published online on: May 3, 2018 https://doi.org/10.3892/etm.2018.6130
Pages: 5461-5468

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate risk factors for renal recurrence in patients with type IV lupus nephritis (LN). Univariate and multivariate analyses were conducted to using the Cox proportional hazard model and the Kaplan‑Meier method. A total 244 patients were diagnosed with type IV LN; 100 (28.49%) relapsed and 144 (41.03%) recovered successfully. Kaplan‑Meier method analysis indicated that patients with type IV LN affecting the digestive tract had high renal recurrence rates. Patients with hyperglobulinemia, positive anti‑ribonucleoprotein and anti‑Sjögren's syndrome type B (anti‑SSB) antibodies, thrombus in the loop or non‑inflammatory necrotizing vasculopathy also had a high recurrence rate. Furthermore, patients achieving partial remission had an increased recurrence rate compared with patients achieving complete remission. Patients undergoing maintenance treatment with glucocorticoids alone had a higher recurrence rate compared with patients who used alternative treatment schemes. Univariate and multivariate regression analyses by the Cox proportional hazard model determined that the effect of systemic lupus erythematosus in the gastrointestinal tract, increased serum globulin levels and positive anti‑SSB antibody at onset were risk factors for the recurrence of LN type IV. The present study demonstrated that clinical risk factors of renal recurrence in patients with LN type IV include LN in the gastrointestinal tract, increased serum globulin levels, positive anti‑SSB antibodies at onset and the use of glucocorticoid‑only maintenance treatment.

View Figures

View References

1	Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N and Winchester RJ: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 25:1271–1277. 1982. View Article : Google Scholar : PubMed/NCBI
2	Hochberg MC: Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 40:17251997. View Article : Google Scholar : PubMed/NCBI
3	Tsang-A-Sioje MW and Bultink IE: Systemic lupus erythematosus: Review of synthetic drugs. Expert Opin Pharmacother. 16:2793–2806. 2015. View Article : Google Scholar : PubMed/NCBI
4	Chan RW, Lai FM, Li EK, Tam LS, Chow KM, Li PK and Szeto CC: The effect of immunosuppressive therapy on the messenger RNA expression of target genes in the urinary sediment of patients with active lupus nephritis. Nephrol Dial Transplant. 21:1534–1540. 2006. View Article : Google Scholar : PubMed/NCBI
5	Alarcón GS, Calvo-Alén J, McGwin G Jr, Uribe AG, Toloza SM, Roseman JM, Fernández M, Fessler BJ, Vilá LM, Ahn C, et al: Systemic lupus erythematosus in a multiethnic cohort: LUMINA XXXV. Predictive factors of high disease activity over time. Ann Rheum Dis. 65:1168–1174. 2006. View Article : Google Scholar : PubMed/NCBI
6	Griffiths B, Mosca M and Gordon C: Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices. Best Pract Res Clin Rheumatol. 19:685–708. 2005. View Article : Google Scholar : PubMed/NCBI
7	Lisnevskaia L, Murphy G and Isenberg D: Systemic lupus erythematosus. Lancet. 384:1878–1888. 2014. View Article : Google Scholar : PubMed/NCBI
8	Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, Balow JE, Bruijn JA, Cook T, Ferrario F, et al: The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 65:521–530. 2004. View Article : Google Scholar : PubMed/NCBI
9	Austin HA III, Muenz LR, Joyce KM, Antonovych TT and Balow JE: Diffuse proliferative LN: Identification of specific pathologic features affecting renal outcome. Kidney Int. 25:689–695. 1984. View Article : Google Scholar : PubMed/NCBI
10	Descombes E, Droz D, Drouet L, Grünfeld JP and Lesavre P: Renal vascular lesions in lupus nephritis. Medicine (Baltimore). 76:355–368. 1997. View Article : Google Scholar : PubMed/NCBI
11	Parikh SV, Nagaraja HN, Hebert L and Rovin BH: Renal flare as a predictor of incident and progressive CKD in patients with lupus nephritis. Clin J Am Soc Nephrol. 9:279–284. 2014. View Article : Google Scholar : PubMed/NCBI
12	Hahn BH, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, Fitzgerald JD, Karpouzas GA, Merrill JT, Wallace DJ, Yazdany J, et al: American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken). 64:797–808. 2012. View Article : Google Scholar : PubMed/NCBI
13	Illei GG, Takada K, Parkin D, Austin HA, Crane M, Yarboro CH, Vaughan EM, Kuroiwa T, Danning CL, Pando J, et al: Renal flares is common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: Long-term followup of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum. 46:995–1002. 2002. View Article : Google Scholar : PubMed/NCBI
14	Gibson KL, Gipson DS, Massengill SA, Dooley MA, Primack WA, Ferris MA and Hogan SL: Predictors of relapse and end stage kidney disease in proliferative lupus nephritis: Focus on children, adolescents, and young adults. Clin J Am Soc Nephrol. 12:1962–1967. 2009. View Article : Google Scholar
15	Contreras G, Tozman E, Nahar N and Metz D: Maintenance therapies for proliferative lupus nephritis: Mycophenolate mofetil, azathioprine and intravenous cyclophosphamide. Lupus. 14 Suppl 1:S33–S38. 2005. View Article : Google Scholar : PubMed/NCBI
16	Moon SJ, Park HS, Kwok SK, Ju J, Choi BS, Park KS, Min JK, Kim HY and Park SH: Predictors of renal relapse in Korean patients with lupus nephritis who achieved remission six months following induction therapy. Lupus. 22:527–537. 2013. View Article : Google Scholar : PubMed/NCBI
17	Imran TF, Yick F, Verma S, Estiverne C, Ogbonnaya-Odor C, Thiruvarudsothy S, Reddi AS and Kothari N: Lupus nephritis: An update. Clin Exp Nephrol. 20:1–13. 2016. View Article : Google Scholar : PubMed/NCBI
18	Pan N, Amigues I, Lyman S, Duculan R, Aziz F, Crow MK and Kirou KA: A surge in anti-dsDNA titer predicts a severe lupus flare within six months. Lupus. 23:293–298. 2014. View Article : Google Scholar : PubMed/NCBI
19	Borg Ter EJ, Horst G, Hummel EJ, Limburg PC and Kallenberg CG: Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus: A long-term, prospective study. Arthritis Rheum. 33:634–643. 1990. View Article : Google Scholar : PubMed/NCBI
20	Coremans IE, Spronk PE, Bootsma H, Daha MR, van der Voort EA, Kater L, Breedveld FC and Kallenberg CG: Changes in antibodies to C1q predict renal relapses in systemic lupus erythematosus. Am J Kidney Dis. 26:595–601. 1995. View Article : Google Scholar : PubMed/NCBI
21	Valões CC, Molinari BC, Pitta AC, Gormezano NW, Farhat SC, Kozu K, Sallum AM, Appenzeller S, Sakamoto AP, Terreri MT, et al: Anti-ribosomal P antibody: A multicenter study in childhood-onset systemic lupus erythematosus patients. Lupus. 26:484–489. 2017. View Article : Google Scholar : PubMed/NCBI
22	Keith MP, Moratz C and Tsokos GC: Anti-RNP immunity: Implications for tissue injury and the pathogenesis of connective tissue disease. Autoimmunity Rev. 6:232–236. 2007. View Article : Google Scholar
23	Lu R, Robertson JM, Bruner BF, Guthridge JM, Neas BR, Nath SK, Kelly JA, Sivils Moser KL, Chakravarty EF, Kamen DL, et al: Multiple autoantibodies display association with lymphopenia, proteinuria, and cellular casts in a large, ethnically diverse SLE patient cohort. Autoimmune Dis. 2012:8196342012.PubMed/NCBI
24	Grootscholten C, Ligtenberg G, Hagen EC, van den Wall Bake AW, de Glas-Vos JW, Bijl M, Assmann KJ, Bruijn JA, Weening JJ, van Houwelingen HC, et al: Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. Kidney Int. 70:732–742. 2006. View Article : Google Scholar : PubMed/NCBI
25	Chan TM, Tse KC, Tang CS, Mok MY and Li FK: Hong Kong Nephrology Study Group: Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol. 16:1076–1084. 2005. View Article : Google Scholar : PubMed/NCBI
26	Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D, Eitner F, Appel GB, Contreras G, Lisk L, et al: Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med. 365:1886–1895. 2011. View Article : Google Scholar : PubMed/NCBI
27	Yap DY, Ma MK, Mok MM, Tang CS and Chan TM: Long-term data on corticosteroids and mycophenolate mofetil treatment in lupus nephritis. Rheumatology (Oxford). 52:480–486. 2013. View Article : Google Scholar : PubMed/NCBI
28	Yap DY and Chan TM: Lupus nephritis in asia: Clinical features and management. Kidney Dis (Basel). 2:100–109. 2015. View Article : Google Scholar
29	Ponticelli C and Moroni G: Hydroxychloroquine in systemic lupus erythematosus (SLE). Expert Opin Drug Saf. 3:411–419. 2017. View Article : Google Scholar
30	Bertsias GK, Tektonidou M, Amoura Z, Aringer M, Bajema I, Berden JH, Boletis J, Cervera R, Dörner T, Doria A, et al: Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 71:1771–1782. 2012. View Article : Google Scholar : PubMed/NCBI
31	Boumpas DT, Austin HA III, Vaughn EM, Klippel JH, Steinberg AD, Yarboro CH and Balow JE: Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet. 340:741–745. 1992. View Article : Google Scholar : PubMed/NCBI
32	Chen Y, Sun J, Zou K, Yang Y and Liu G: Treatment for lupus nephritis: An overview of systematic reviews and meta-analyses. Rheumatol Int. 7:1089–1099. 2017. View Article : Google Scholar
33	Rovin BH and Parikh SV: Lupus nephritis: The evolving role of novel therapeutics. Am J Kidney Dis. 63:677–690. 2014. View Article : Google Scholar : PubMed/NCBI